公开(公告)号：US20230303705A1

公开(公告)日：2023-09-28

申请号：US17917113

申请日：2021-04-09

申请人： Seattle Children's Hospital (dba Seattle Children's Research Institute) ,  Provincial Health Services Authority ,  University of Pittsburgh - of the Commonwealth System of Higher Education

发明人： Rimas J. Orentas ,  Dimiter Stanchev Dimitrov ,  Poul H. Sorensen ,  Haifeng Zhang ,  Wei Li

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  C07K2319/02 ,  C07K2319/03

摘要： Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).

公开(公告)号：US20240026012A1

公开(公告)日：2024-01-25

申请号：US18027305

申请日：2021-10-08

申请人： Seattle Children's Hospital (dba Seattle Children's Research Institute ,  University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Rimas J. Orentas ,  Dimiter Stanchev Dimitrov ,  Wei LI ,  Du-Sun Baek

IPC分类号： C07K16/28 ,  C12N15/86 ,  A61K39/00 ,  C12N5/078 ,  A61K35/17

CPC分类号： C07K16/2863 ,  C12N15/86 ,  A61K39/4631 ,  C12N5/0634 ,  A61K35/17 ,  A61K2239/21 ,  A61K2239/22 ,  C12N2510/00

摘要： Some embodiments of the methods and compositions provided herein include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an FGFR4 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) acidic box that bind to an FGFR4 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to fibroblast growth factor receptor 4 (FGFR4). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an FGFR4-expressing cancer, such as a rhabdomyosarcoma.